Printer Friendly

ZILA REPORTS PROGRESS IN EFFORT TO OBTAIN FDA APPROVAL FOR ORASCAN ORAL CANCER DETECTION PRODUCT.

ZILA REPORTS PROGRESS IN EFFORT TO OBTAIN FDA APPROVAL FOR ORASCAN
 ORAL CANCER DETECTION PRODUCT.
 PHOENIX, Sept. 9 /PRNewswire/ -- Zila Pharmaceuticals, Inc., a subsidiary of Zila, Inc. (NASDAQ: ZILA), reported progress in its efforts to obtain governmental approval to market the first early detection system for oral cancer.
 Following a meeting Sept. 1 with senior officials of the U.S. Food and Drug Administration (FDA), Zila President Joseph Hines said: "We believe we made significant progress toward gaining timely regulatory approval for our Orascan OTB System by clarifying the path toward clearance. We are quite pleased with the reception we received at the FDA. The agency has requested additional data, which we are preparing and will submit during the week of Sept. 7."
 Hines said three factors should support definitive action within a reasonable time frame:
 "First, there is an enormous volume of published, peer-reviewed research supporting the scientific principles that underlie our product's components and application.
 "Second, there is widespread, successful experience with the Orascan-type methodology among dentists throughout the U.S. and the world. (Use has been largely confined to institutional facilities such as major hospitals and dental schools, owing to the difficulty of formulating appropriate, consistent and stable components on an ad hoc basis -- problems resolved by Zila's Orascan.)
 "And third, the Bush administration has already recognized the desperate need for effective oral cancer screening. The U.S. Department of Health & Human Services, in its report 'Healthy People 2000,' set a national goal of significantly reduced oral cancer mortality, emphasizing prompt diagnosis and early treatment. There is no other early detection system available to dentists or physicians; Orascan will be the first ever."
 The government reports that 31,000 new oral cancer cases and 8,150 deaths were expected in 1991. Treatment for advanced cases of oral cancer is often painful and disfiguring; annual costs of treatment exceed $665 million. Yet oral cancer, when it is detected early, is the most easily cured of all the major cancer types.
 Zila announced in May that it is seeking Canadian government approval to market Orascan in that country. Hines said, "We have been working very closely with the Canadian Health Protection Branch. As a result, we feel confident our application is moving rapidly through the agency." Steps have also been taken to gain regulatory approval in the United Kingdom, Spain and Italy, with the objective of obtaining marketing clearance for Orascan in all European Community nations.
 -0- 9/9/92
 /NOTE: Orascan is a registered trademark./
 /CONTACT: Joseph Hines of Zila, 602-266-6700/
 (ZILA) CO: Zila Pharmaceuticals, Inc.; U.S. Food and Drug Administration ST: Arizona IN: MTC SU:


TW -- DC013 -- 7531 09/09/92 13:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 9, 1992
Words:448
Previous Article:SEARLE ACQUIRES CZECH MEDICAL PRODUCTS DISTRIBUTION COMPANY
Next Article:GM MASTERCARD PROMISES TO TURN PLASTIC INTO STEEL
Topics:


Related Articles
ZILA, INC. SEEKS FDA MARKETING APPROVAL FOR ORAL LESION DETECTION DEVICE
ZILA'S ORASCAN APPLICATION ADVANCES AT FDA
ZILA PHARMACEUTICALS, INC., APPROVED TO MARKET ORASCAN IN AUSTRALIA
INSURANCE COVERAGE FOR ORASCAN TAKES EFFECT IN CANADA
ZILA, INCORPORATED TO EXPAND VIA MAJOR ACQUISITION
ZILA'S ORAL CANCER DETECTION SYSTEM GAINS UK APPROVAL
FDA ACTS ON ZILA'S ORASCAN(TM); COMPANY READIES DOMESTIC PRODUCTION TO SUPPORT EXPORT SALES
ZILA ANNOUNCES NEW PATENT FOR ORASCAN(TM) TECHNOLOGY
New Study Shows Zila's Oral Cancer Diagnostic Test More Than Doubles Detection Rates
Zila to Market OraTest in Republic of China

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters